<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Mhealth Uhealth</journal-id><journal-id journal-id-type="publisher-id">mhealth</journal-id><journal-id journal-id-type="index">13</journal-id><journal-title>JMIR mHealth and uHealth</journal-title><abbrev-journal-title>JMIR Mhealth Uhealth</abbrev-journal-title><issn pub-type="epub">2291-5222</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v14i1e93991</article-id><article-id pub-id-type="doi">10.2196/93991</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Effect of Teledermatologist Supervision in AI Skin Cancer Apps on Patients&#x2019; Trust and Adherence Intentions: Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Swain</surname><given-names>Ritwik</given-names></name><degrees>BSc, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Masic</surname><given-names>Mihaela</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Staal</surname><given-names>Justine</given-names></name><degrees>BSc, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dangerman</surname><given-names>Natalie</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barendse</surname><given-names>Elise</given-names></name><degrees>BSc, MSc</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wakkee</surname><given-names>Marlies</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zwaan</surname><given-names>Laura</given-names></name><degrees>BSc, MSc, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><institution>Department of Public Health, Erasmus MC</institution><addr-line>Dr Molewaterplein 40</addr-line><addr-line>Rotterdam</addr-line><addr-line>South Holland</addr-line><country>The Netherlands</country></aff><aff id="aff2"><institution>Department of Social and Behavioural Sciences, Erasmus University Rotterdam</institution><addr-line>Rotterdam</addr-line><addr-line>South Holland</addr-line><country>The Netherlands</country></aff><aff id="aff3"><institution>Department of Quality and Patient Care, Erasmus MC</institution><addr-line>Rotterdam</addr-line><addr-line>South Holland</addr-line><country>The Netherlands</country></aff><aff id="aff4"><institution>Deparment of Dermatology, Erasmus MC Cancer Institute, University Medical Center</institution><addr-line>Rotterdam</addr-line><addr-line>South Holland</addr-line><country>The Netherlands</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Brini</surname><given-names>Stefano</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Hartanto</surname><given-names>Andree</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>Kakraba</surname><given-names>Samuel</given-names></name></contrib><contrib contrib-type="reviewer"><name name-style="western"><surname>McRoy</surname><given-names>Susan</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Ritwik Swain, BSc, MSc, PhD, Department of Public Health, Erasmus MC, Dr Molewaterplein 40, Rotterdam, South Holland, The Netherlands, +31 10 704 0704; <email>secretariaat.mgz@erasmusmc.nl</email></corresp></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2026</year></pub-date><volume>14</volume><elocation-id>e93991</elocation-id><history><date date-type="received"><day>23</day><month>02</month><year>2026</year></date><date date-type="rev-recd"><day>26</day><month>08</month><year>2026</year></date><date date-type="accepted"><day>01</day><month>09</month><year>2026</year></date></history><copyright-statement>&#x00A9; Ritwik Swain, Mihaela Masic, Justine Staal, Natalie Dangerman, Elise Barendse, Marlies Wakkee, Laura Zwaan. Originally published in JMIR mHealth and uHealth (<ext-link ext-link-type="uri" xlink:href="https://mhealth.jmir.org">https://mhealth.jmir.org</ext-link>), 17.11.2026. </copyright-statement><copyright-year>2026</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://mhealth.jmir.org/">https://mhealth.jmir.org/</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://mhealth.jmir.org/2026/1/e93991"/><abstract><sec><title>Background</title><p>Skin cancer incidence is rising globally, increasing pressure on dermatology services and making efficient triage increasingly important. AI-driven skin cancer mobile health apps may help address this need, but their usefulness depends on whether users trust the advice and intend to follow it. Teledermatologist supervision has been proposed to combine AI efficiency with human clinical oversight, but dermatologist shortages make it critical to understand whether such supervision improves patient trust and adherence at the population level, or whether AI-only advice suffices for most users.</p></sec><sec><title>Objective</title><p>This study tests whether teledermatologist supervision in an AI-driven skin cancer app affects patient trust and adherence intentions, compared with AI-only advice, and whether these effects differ by motivational context and risk assessment level.</p></sec><sec sec-type="methods"><title>Methods</title><p>The randomized controlled, online vignette experiment with repeated measures was conducted from May to June 2025 as a single-center study among Dutch adults via an academic hospital-based patient panel. Eligible participants were adult members of the Erasmus MC Digital Patient Panel invited by email; those not completing all 4 vignette trials were excluded from the analysis. Participants completed 4 simulated mobile app scenarios varying in advice source (AI-only vs hybrid teledermatologist and AI) and risk assessment level (high vs low). The primary outcomes were trust in the advice (0&#x2010;100 scale) and adherence intention (recoded 3-level ordinal scale). Mixed-effects models were used to analyze the data.</p></sec><sec sec-type="results"><title>Results</title><p>Of the 2707 patient panel members, 879 participated (response rate: 32.5%). Participants were aged 18 to 93 (mean 62.5, SD 12.64) years; 50.4% (n=443) were female, and 21.4% (n=188) had a history of skin cancer. Participants were randomly allocated to motivation conditions (concern: n=438 vs curiosity: n=441). Trust was higher for hybrid advice than AI-only advice (mean 76.9, SE 0.73 vs mean 65.7, SE 0.73; estimated difference 11.98; partial <italic>&#x03B7;</italic>&#x00B2;=0.22; <italic>P</italic>&#x003C;.001). The odds of adherence were 1.7 times greater with hybrid vs AI-only (odds ratio 1/0.59=1.7, 95% CI 1.28-2.22; <italic>P</italic>&#x003C;.001). High-risk assessments increased adherence (odds ratio 2.9, 95% CI 2.2-3.8; <italic>P</italic>&#x003C;.001), with a moderated effect by motivation (<italic>P</italic>=.03), showing stronger adherence with concern vs curiosity. The effect of advice source on adherence was fully mediated by trust.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Teledermatologist supervision of AI-based advice robustly increased patient trust and adherence intentions, particularly for high-risk assessments and concerned users. Our experiment is innovative in testing teledermatologist supervision in a population-level AI skin cancer app and in examining how motivational context shapes responses to advice. Unlike studies focused on postreferral teledermatology or chatbot-based advice, this study isolates the effect of hybrid AI-human advice in a store-and-forward screening context. These findings suggest that developers and health care implementers may consider integrating teledermatologist supervision to maximize patient trust of and adherence to advice, potentially improving triaging efficiency and safety.</p></sec><sec><title>Trial Registration</title><p>Open Science Framework 64pjn; https://osf.io/64pjn</p></sec></abstract><kwd-group><kwd>mobile health</kwd><kwd>mHealth apps</kwd><kwd>health behavior</kwd><kwd>patient motivation</kwd><kwd>user experience</kwd><kwd>human-AI collaboration</kwd><kwd>dermatology</kwd><kwd>teledermatology</kwd><kwd>mHealth</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><sec id="s1-1"><title>Background</title><p>Globally, the incidence of both melanoma [<xref ref-type="bibr" rid="ref1">1</xref>-<xref ref-type="bibr" rid="ref3">3</xref>] and other skin cancer [<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref>] is increasing, with related deaths projected to increase by 68% from 2020 to 2040 [<xref ref-type="bibr" rid="ref6">6</xref>]. The increased incidence compounds the already significant strain on dermatology services, causing delays in diagnosis and treatment in some regions [<xref ref-type="bibr" rid="ref7">7</xref>]. Teledermatology [<xref ref-type="bibr" rid="ref8">8</xref>], whereby a dermatologist makes their assessment remotely using digital technologies, has helped address this challenge by postreferral triaging [<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>], achieving improved accessibility and cost savings of 6.3% to 45.3% per patient [<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref>] by potentially avoiding unnecessary appointments with the general practitioner [<xref ref-type="bibr" rid="ref13">13</xref>]. However, widescale teledermatology is likely unrealistic, given global dermatologist shortages [<xref ref-type="bibr" rid="ref14">14</xref>-<xref ref-type="bibr" rid="ref16">16</xref>].</p><p>Using AI in place of teledermatology has been proposed [<xref ref-type="bibr" rid="ref17">17</xref>-<xref ref-type="bibr" rid="ref19">19</xref>], as experiments found AI to diagnose lesion images more accurately than both nonspecialists [<xref ref-type="bibr" rid="ref20">20</xref>] and dermatologists [<xref ref-type="bibr" rid="ref21">21</xref>]. Certain use cases for AI in dermatology are promising (Du&#x2010;Harpur et al [<xref ref-type="bibr" rid="ref22">22</xref>]), for example, as an aid for diagnosing [<xref ref-type="bibr" rid="ref23">23</xref>-<xref ref-type="bibr" rid="ref25">25</xref>] or in triaging [<xref ref-type="bibr" rid="ref26">26</xref>]. In fact, both AI alone and AI with a dermatologist check were found to be more cost-effective in postreferral triage than face-to-face assessments or teledermatology [<xref ref-type="bibr" rid="ref26">26</xref>]. Combining teledermatology and AI postreferral enhances care quality, streamlines processes, and reduces costs [<xref ref-type="bibr" rid="ref27">27</xref>], and consequently, hybrid models are recommended to help expand access [<xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref>] and are often preferred by patients [<xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref>]. However, less research has been conducted on AI-teledermatology apps at the population level, which can face practical challenges, such as users not being sufficiently reassured by low-risk assessments and seeking doctor appointments anyway, as found in a Dutch study [<xref ref-type="bibr" rid="ref30">30</xref>]. The app in the study [<xref ref-type="bibr" rid="ref30">30</xref>] increased premalignant or malignant lesion detection by 32%, while also tripling to quadrupling benign lesion claims, indicating population-level overdiagnosis. Furthermore, patients receiving a low-risk assessment from the app had twice as many claims for benign skin lesions, suggesting that they were neither reassured by the app nor their general practitioner [<xref ref-type="bibr" rid="ref30">30</xref>]. Therefore, adherence to low-risk advice for population-level apps needs to be high to mitigate the risk of increased health care demand. Using AI-based apps to prevent unnecessary appointments appears achievable, as a feasibility study reported that 54% of patients who visited the general practitioner with benign lesions and had low-risk app ratings would have felt reassured enough to cancel their general practitioner visit [<xref ref-type="bibr" rid="ref13">13</xref>].</p><p>People&#x2019;s adherence may differ based on their reason for using the app. For highly concerned users, the perceived threat [<xref ref-type="bibr" rid="ref31">31</xref>] of skin cancer cannot be alleviated by an algorithm [<xref ref-type="bibr" rid="ref32">32</xref>], so they will still seek follow-up appointments regardless of the app&#x2019;s risk assessment. In contrast, users motivated by curiosity, which is often a reason to seek health information [<xref ref-type="bibr" rid="ref33">33</xref>], may be less inclined to follow-up with their general practitioner even if advised by their app. How users&#x2019; adherence is influenced by motivational context (ie, concern or curiosity) and risk assessment (ie, low or high risk) is unexplored, yet it is critical to understand if AI-based apps in dermatology are able to alleviate health care demand at the population level. Trust is key [<xref ref-type="bibr" rid="ref34">34</xref>] as patients who trust their clinicians show greater confidence in clinicians&#x2019; decisions [<xref ref-type="bibr" rid="ref35">35</xref>] and better adherence [<xref ref-type="bibr" rid="ref36">36</xref>,<xref ref-type="bibr" rid="ref37">37</xref>], and presumably the same would apply to health apps. An online experiment [<xref ref-type="bibr" rid="ref38">38</xref>] found that trust in advice is highest when given by a doctor, followed by human-AI collaboration, and least when offered by AI alone. However, the experiment [<xref ref-type="bibr" rid="ref38">38</xref>] involved real-time involvement of a doctor, but in teledermatology, a store-and-forward format [<xref ref-type="bibr" rid="ref39">39</xref>] is common, where patients upload photos [<xref ref-type="bibr" rid="ref28">28</xref>] for later assessment. Furthermore, the experiment&#x2019;s [<xref ref-type="bibr" rid="ref38">38</xref>] AI-only option was a chatbot, not an AI photo analysis.</p><p>Although population-level AI skin cancer apps have shown feasibility [<xref ref-type="bibr" rid="ref13">13</xref>], it remains unclear whether teledermatologist supervision improves users&#x2019; trust and intended adherence when advice is delivered in a patient-facing, store-and-forward format. This study aims to address this gap by assessing user responses to store-and-forward&#x2013;style, AI-based dermatology apps using a vignette-based experimental design. Vignette experiments have been established as a valid, reliable, and practical method in health care research, offering strong criterion validity while bypassing the ethical and practical constraints of real-world experiments [<xref ref-type="bibr" rid="ref40">40</xref>].</p></sec><sec id="s1-2"><title>Research Question and Hypotheses</title><p>The current study poses the question: How do advice source (AI alone or hybrid) and user motivation (curiosity vs concern) shape patient trust and adherence intentions to the provided advice within the context of AI-supported teledermatology? Three preregistered hypotheses are posed:</p><list list-type="order"><list-item><p>H1: Trust (H1a) and adherence intentions (H1b) will be higher for hybrid advice vs AI-only (main effect of advice source on trust and adherence intentions).</p></list-item><list-item><p>H2: High-risk assessments will increase adherence intentions (H2a), particularly in the concern condition (H2b) (a main effect of risk assessment and an interaction of motivation and risk assessment on adherence intentions).</p></list-item><list-item><p>H3: Trust will mediate the effect of advice source on adherence intentions.</p></list-item></list></sec></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Trial Design</title><p>Our randomized controlled, online vignette experiment with repeated measures uses a 2&#x00D7;2&#x00D7;2 design, with motivational context (concern vs curiosity) as a between-participants factor and advice source (AI-only vs hybrid) and risk assessment (high vs low) as within-participants factors. The dependent variables include trust and adherence to medical advice. <xref ref-type="fig" rid="figure1">Figure 1</xref> presents a study design flowchart. The public was not involved in the design, conduct, or reporting of the trial.</p><fig position="float" id="figure1"><label>Figure 1.</label><caption><p>Experimental design flowchart for a 2&#x00D7;2&#x00D7;2 randomized vignette experiment among Dutch adults recruited from the Erasmus MC Patient Panel, Rotterdam, the Netherlands, May to June 2025. Participants were randomized to curiosity or concern, and then completed 4 simulated app trials varying in advice source (AI-only vs hybrid teledermatologist + AI) and risk assessment (low vs high). Participants were assigned to motivation conditions between participants, then received both advice source types and risk assessment levels in randomized order (within participants). Each completed 4 trials of risk assessments, with trust and adherence intentions measured after each trial.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="mhealth_v14i1e93991_fig01.png"/></fig></sec><sec id="s2-2"><title>Sample Size</title><p>An a priori power analysis was conducted in G*Power 3.1.9.6 [<xref ref-type="bibr" rid="ref41">41</xref>] for the planned within-between interaction in a repeated measures ANOVA (test family: <italic>F</italic> tests; statistical test: ANOVA: repeated measures, within-between interaction). Because no directly comparable prior studies were available, we conservatively assumed a small-to-medium effect size of f(V)=0.25 [<xref ref-type="bibr" rid="ref42">42</xref>], &#x03B1;=.05, power=0.80, 2 groups (motivation factor), 4 measurements (2&#x00D7;2 within-participants factors), and nonsphericity correction (<italic>&#x03F5;</italic>=1). This yielded a minimum total sample size of 168 [<xref ref-type="bibr" rid="ref41">41</xref>].</p></sec><sec id="s2-3"><title>Materials</title><p>The experiment was created using Qualtrics and conducted in Dutch. No personnel were required to conduct the study as it was automated and online. The experiment included an introduction to AI, experiment instructions (<xref ref-type="supplementary-material" rid="app1">Multimedia Appendix 1</xref>), 2 motivation texts, and image stimuli for the motivation conditions (<xref ref-type="supplementary-material" rid="app2">Multimedia Appendix 2</xref>). Additionally, 4 simulated mobile health app trials, varying in combinations between advice source and risk assessment, were included (see <xref ref-type="fig" rid="figure2">Figure 2</xref> and <xref ref-type="supplementary-material" rid="app3">Multimedia Appendix 3</xref>).</p><fig position="float" id="figure2"><label>Figure 2.</label><caption><p>Simulated medical risk assessment outputs used in a randomized vignette experiment among Dutch adults recruited from the Erasmus MC Patient Panel, Rotterdam, the Netherlands, May to June 2025. Each risk assessment also reminds participants of the advice source and provides follow-up advice. App images were created using Canva and AI.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="mhealth_v14i1e93991_fig02.png"/></fig></sec><sec id="s2-4"><title>Ethical Considerations</title><p>This study was approved by the Medical Ethics Committee of Erasmus MC (MEC-2025&#x2010;0371) and conducted in accordance with the procedures of the Erasmus MC Digital Patient Panel [<xref ref-type="bibr" rid="ref43">43</xref>]. Informed consent was obtained through panel membership registration, by which members agree to be approached for research participation and may opt out of any individual study at any time; no separate consent procedure was required within the study itself. All data were collected anonymously through the panel infrastructure; no personally identifiable information was linked to experimental responses, ensuring participant confidentiality. Participants received no financial or material compensation for participation. No harms were posed on participants as it was an online study, and no concomitant care was provided. All efforts have been made to ensure that individual participants cannot be identified in any images of the manuscript or supplementary material.</p></sec><sec id="s2-5"><title>Procedure</title><p>As this study involved a hypothetical vignette-based experiment assessing patient-reported trust and adherence intentions rather than a health-related intervention delivered to patients or a health-related outcome, prospective trial registration was not required under International Committee of Medical Journal Editors guidelines [<xref ref-type="bibr" rid="ref44">44</xref>]. The study was nonetheless preregistered on the Open Science Framework [<xref ref-type="bibr" rid="ref45">45</xref>] to enhance transparency of our research on May 26, 2025, after recruitment had begun but before any data inspection, cleaning, or analysis. The experiment was emailed to 2707 panel members between May 22 and June 10, 2025, with the first response being on May 22. The data collection period was defined by the panel administrators. After demographics and an AI attitudes scale, participants were randomly assigned by Qualtrics to motivation conditions (concern or curiosity; see <xref ref-type="supplementary-material" rid="app2">Multimedia Appendix 2</xref>). They completed 4 trials in 2 randomized blocks, varying advice source (AI-only vs hybrid) and risk assessment (high vs. low). Each trial presented 1 advice output, followed by trust and adherence intention measures.</p><p>Consequently, each participant saw 4 assessment outputs, 1 high-risk and 1 low-risk per advice source. After each assessment, participants answered 1 item measuring trust and another measuring their intention to adhere to the advice. Finally, participants were debriefed about the aim of the study.</p></sec><sec id="s2-6"><title>Outcomes</title><p>In a preexperiment questionnaire, participants answered questions on demographic data (age, gender, and skin cancer history) and their attitudes toward AI in health care, measured using a Dutch version of the validated 4-item AI Attitude Scale (AIAS-4) [<xref ref-type="bibr" rid="ref46">46</xref>], with participants indicating their level of agreement on scales from 1 (&#x201C;Not at all&#x201D;) to 10 (&#x201C;Completely agree&#x201D;). After each trial, trust was rated on a continuous slider (0=no trust, 100=full trust) with the question &#x201C;How much trust do you have in this result?&#x201D; This single-item format was chosen to minimize respondent burden across 4 repeated trials. While single-item measures cannot capture all dimensions of trust, they can provide reliable and valid indicators of overall trust judgments [<xref ref-type="bibr" rid="ref47">47</xref>].</p><p>Adherence was assessed by asking &#x201C;What would you do next regarding your mole?&#x201D; Participants selected 1 of 5 response options (<xref ref-type="table" rid="table1">Table 1</xref>), which were recoded, with input from a clinician, into a 3-level ordinal adherence variable for both risk assessment levels. The recoding scheme was designed to reflect medically meaningful levels of adherence. Because the clinical implications of the same response differ depending on whether the AI advice indicated high or low risk, the classification of the responses varied by risk condition.</p><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Recoding of postvignette adherence intention responses into a 3-level ordinal outcome in a randomized vignette experiment on an AI-supported skin cancer app among Dutch adults recruited from the Erasmus MC Patient Panel, Rotterdam, the Netherlands, May to June 2025<sup><xref ref-type="table-fn" rid="table1fn1">a</xref></sup>.</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Response option</td><td align="left" valign="bottom">High-risk advice</td><td align="left" valign="bottom">Low-risk advice</td><td align="left" valign="bottom">Justification</td></tr></thead><tbody><tr><td align="left" valign="top">&#x201C;I would make an appointment with my GP the same day.&#x201D;</td><td align="left" valign="top">High adherence</td><td align="left" valign="top">Neglect</td><td align="left" valign="top">It is high adherence for high risk because there is same-day intention to make an appointment. Conversely, it is neglect for low risk because an appointment is made.</td></tr><tr><td align="left" valign="top">&#x201C;I would make an appointment within a week.&#x201D;</td><td align="left" valign="top">Moderate adherence</td><td align="left" valign="top">Neglect</td><td align="left" valign="top">For high risk, this option is moderate adherence because an appointment is still made but with suboptimal urgency. Conversely, it is neglect for low risk because an appointment is made.</td></tr><tr><td align="left" valign="top">&#x201C;I would make an appointment when I have time; I am not immediately worried.&#x201D;</td><td align="left" valign="top">Neglect</td><td align="left" valign="top">Moderate adherence</td><td align="left" valign="top">For high risk, this option is clearly neglect because there is a lack of clear intention to make a doctor&#x2019;s appointment. For low risk, it is moderate adherence because they might make an appointment but there is not a clear intention.</td></tr><tr><td align="left" valign="top">&#x201C;I would monitor the mole and only make an appointment if it changes.&#x201D;</td><td align="left" valign="top">Neglect</td><td align="left" valign="top">High adherence</td><td align="left" valign="top">For high risk, this option is considered neglect because the user intends to wait for further signs before making an appointment. In contrast, for low risk, it is desirable that an appointment is not made, unless the mole changes.</td></tr><tr><td align="left" valign="top">&#x201C;I would not seek any further medical assessment.&#x201D;</td><td align="left" valign="top">Neglect</td><td align="left" valign="top">High adherence</td><td align="left" valign="top">For high risk, this decision is clear neglect because no intention to make an appointment is present. In contrast, for low risk, it is high adherence because there is no sign that the user intends to make an appointment.</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>Participants were asked &#x201C;What would you do next regarding your mole?&#x201D;</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-7"><title>Statistical Methods</title><p>Analyses were conducted using both SPSS (version: 28.0.1.0(142); IBM Statistics) and RStudio (2025.05.1 Build 513). For H1, a linear mixed-effects model (LMM) was used with trust as the continuous outcome, advice source and risk assessment as within-participants factors, motivation as a between-participants covariate, and participant as a random intercept. Although the Shapiro-Wilk test was significant, the residuals appeared normally distributed and no other assumptions were violated, and we proceeded with the LMM. Effect size was calculated using the following equation: <inline-formula><mml:math id="ieqn1"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mrow><mml:msubsup><mml:mi>&#x03B7;</mml:mi><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mtext>=</mml:mtext><mml:mtext>&#x00A0;</mml:mtext><mml:mfrac><mml:mrow><mml:mi>F</mml:mi><mml:mo>&#x00D7;</mml:mo><mml:mi>d</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mo>&#x00D7;</mml:mo><mml:mi>d</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mtext>+</mml:mtext><mml:mi>d</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math></inline-formula></p><p>For H1b and H2, a cumulative link mixed model (CLMM) [<xref ref-type="bibr" rid="ref48">48</xref>,<xref ref-type="bibr" rid="ref49">49</xref>] was used given the ordinal nature of adherence intentions. Category counts were sufficient. Logit plots supported proportional odds assumption for advice source and motivation, but risk assessment violated it. To address this, 2 binary generalized linear mixed model sensitivity analyses were conducted: 1 contrasting high adherence vs moderate adherence/neglect combined and 1 contrasting neglect vs high/moderate adherence combined. The latter reflects the theoretically motivated distinction between engagement (high and moderate adherence) and complete disengagement (neglect). The results of both sensitivity analyses are reported alongside the primary CLMM findings. A CLMM was conducted with adherence intentions, predicted by the independent variables: advice source, risk assessment, motivation, and their interactions, with a random intercept for participant ID.</p><p>For H3, the main effects of trust, advice source, and their interaction on adherence intentions were tested using a CLMM, with no proportional odds assumption violations for any predictor. A mediation analysis was conducted to test the indirect effect of advice source on adherence intentions via trust as the product of 2 paths: source &#x2192; trust and trust &#x2192; adherence intentions, assessed through a Monte Carlo simulation with 10,000 draws. To obtain unbiased estimates, both the CLMM for trust&#x2019;s effect on adherence intentions (path b) and the LMM for source&#x2019;s effect on trust (path a) were rerun without any interaction terms.</p></sec><sec id="s2-8"><title>Reporting Guidelines</title><p>We reported this randomized vignette experiment in accordance with [<xref ref-type="bibr" rid="ref50">50</xref>] the CONSORT (Consolidated Standards of Reporting Trials) abstract extension [<xref ref-type="bibr" rid="ref51">51</xref>], CONSORT-EHEALTH (Consolidated Standards of Reporting Trials of Electronic and Mobile Health Applications and Online Telehealth) guidelines (<xref ref-type="supplementary-material" rid="app8">Checklist 1</xref>) [<xref ref-type="bibr" rid="ref52">52</xref>], and TIDieR (Template for Intervention Description and Replication) guidelines [<xref ref-type="bibr" rid="ref53">53</xref>].</p></sec><sec id="s2-9"><title>Changes to Trial Protocol</title><p>We made the following four changes compared to the preregistration [<xref ref-type="bibr" rid="ref45">45</xref>]:</p><list list-type="order"><list-item><p>A wording clarification for H2</p></list-item><list-item><p>Substitution of mixed-factor ANOVA with LMM for trust</p></list-item><list-item><p>Substitution of mixed-factor ANOVA with CLMM for adherence</p></list-item><list-item><p>Replacement of the regression-based mediation with Monte Carlo mediation using mixed-model path estimates</p></list-item></list><p>Points 2 and 3 allow for random intercepts for each participant, enhancing the modeling of individual variability [<xref ref-type="bibr" rid="ref54">54</xref>]. A full account of deviations from the preregistration, including justification for each change, is documented in a Transparent Changes file on the OSF project page [<xref ref-type="bibr" rid="ref45">45</xref>] and in <xref ref-type="supplementary-material" rid="app4">Multimedia Appendix 4</xref>.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Participant Flow</title><p>The study received 1040 responses in total. Of the 2707 patient panel members, there were 879 full completions, resulting in a response rate of 32.5% (<xref ref-type="fig" rid="figure3">Figure 3</xref>).</p><fig position="float" id="figure3"><label>Figure 3.</label><caption><p>CONSORT (Consolidated Standards of Reporting Trials) flow diagram of participant screening, randomization, exclusions, and analysis in the randomized vignette experiment among Dutch adults recruited from the Erasmus MC Patient Panel, Rotterdam, the Netherlands, May to June 2025.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="mhealth_v14i1e93991_fig03.png"/></fig><p>Excluded participants were slightly older than included participants (mean 64.9, SD 12.31 y vs mean 62.5, SD 12.62 y; <italic>t</italic><sub>1030</sub>=2.19, <italic>d</italic>=0.19; <italic>P</italic>=.03). There were no statistically significant differences in baseline AI attitudes (mean 5.95, SD 2.33 vs mean 6.17, SD 2.08; <italic>P</italic>=.30), gender distribution (<italic>P</italic>=.22), personal skin cancer history (<italic>P</italic>=.82), or motivation assignment (<italic>P</italic>=.95).</p></sec><sec id="s3-2"><title>Baseline Data</title><p>The median completion time was 4 minutes 56 seconds (IQR 2:55-3:45; range 1:28-175:26). Participants had a mean age of 62.5 (SD 12.64, range 18&#x2010;93) years with balanced gender distribution (female: n=443, 50.4%; male: n=433, 49.3%). A total of 188 (21%) reported a prior skin cancer diagnosis. The average AIAS-4 score was 6.17 (SD 2.08; n=879), indicating a slightly positive attitude toward AI.</p></sec><sec id="s3-3"><title>Effects on Primary Outcomes of Trust and Adherence Intentions</title><sec id="s3-3-1"><title>H1a Influence of Advice Source on Trust</title><p>The LMM revealed a significant main effect of advice source on trust (<italic>F</italic><sub>1,2643</sub>=758.50; <italic>P</italic>&#x003C;.001); trust was higher for hybrid (estimated marginal mean 76.88, SE 0.73) than AI-only (estimated marginal mean 65.68, SE 0.73), with an estimated difference of 11.98 (95% CI 10.39-13.58). This relatively narrow interval indicates a precise estimate of the source effect on trust. Advice source&#x2019;s effect size was large (partial <italic>&#x03B7;</italic>&#x00B2;=0.22), supporting hypothesis H1a that participants trust hybrid-based assessments more than AI-only assessments. Table S1 in <xref ref-type="supplementary-material" rid="app5">Multimedia Appendix 5</xref> shows the tests of fixed effects, while Table S2 in <xref ref-type="supplementary-material" rid="app5">Multimedia Appendix 5</xref> shows the estimates of fixed effects.</p></sec><sec id="s3-3-2"><title>H1b and H2: Influence of Advice Source, Risk Assessment, and Motivational Context on Adherence Intentions</title><p>In all CLMMs, odds ratios (ORs) reflect the cumulative odds of being in a higher adherence intention category, with values greater than 1 indicating increased odds of stronger adherence intentions. The CLMM found a significant main effect of advice source (<italic>b</italic>=&#x2013;0.52, SE 0.14; <italic>z</italic>=&#x2013;3.84; <italic>P</italic>&#x003C;.001) on adherence intentions (see the full table in <xref ref-type="supplementary-material" rid="app6">Multimedia Appendix 6</xref>). The OR for hybrid compared to AI was approximately 0.59 (OR 1/0.59=1.7, 95% CI 1.28-2.22; <italic>P</italic>&#x003C;.001), indicating that participants were about 1.7 times more likely to be in a higher adherence intention category under the hybrid advice source condition compared to the AI-only advice, supporting hypothesis H1b. The CI suggests a reasonably precise estimate of this effect.</p><p>The CLMM also found a significant main effect of risk assessment on adherence intentions (<italic>b</italic>=&#x2013;1.07, SE =0.14; <italic>z</italic>=&#x2013;7.86; <italic>P</italic>&#x003C;.001). Because lower scores indicate stronger adherence intentions, this means that participants who received a high-risk assessment were about 3 times more likely (OR 2.9, 95% CI 2.2-3.8) to report higher adherence intentions compared to those with low-risk diagnoses. The relatively narrow CI indicates a precise estimate of the risk effect.</p><p>Importantly, a significant interaction between risk and motivation was found (<italic>riskHigh &#x00D7; motivationCuriosity; b</italic>=0.40, SE =0.19; <italic>z</italic>=2.13; <italic>P</italic>=.03). This indicates that the boost in adherence intentions associated with high risk was weaker among curiosity-motivated participants compared to those motivated by concern, which can also be seen in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="t2" position="float"><label>Table 2.</label><caption><p>Distribution of adherence intention responses by motivation condition, advice source, and risk assessment in a randomized vignette experiment among Dutch adults recruited from the Erasmus MC Patient Panel, Rotterdam, the Netherlands, May to June 2025<sup><xref ref-type="table-fn" rid="table2fn1">a</xref></sup>.</p></caption><table id="table2" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Motivation</td><td align="left" valign="bottom">Source</td><td align="left" valign="bottom">Risk</td><td align="left" valign="bottom">Total, n</td><td align="left" valign="bottom">High adherence intention, n (%)</td><td align="left" valign="bottom">Moderate adherence intention, n (%)</td><td align="left" valign="bottom">Neglect, n (%)</td></tr></thead><tbody><tr><td align="left" valign="top">Concern</td><td align="left" valign="top">AI</td><td align="left" valign="top">High</td><td align="left" valign="top">438</td><td align="left" valign="top">264 (60.3)</td><td align="left" valign="top">142 (32.4)</td><td align="left" valign="top">32 (7.3)</td></tr><tr><td align="left" valign="top">Concern</td><td align="left" valign="top">AI</td><td align="left" valign="top">Low</td><td align="left" valign="top">438</td><td align="left" valign="top">192 (43.8)</td><td align="left" valign="top">89 (20.3)</td><td align="left" valign="top">157 (35.8)</td></tr><tr><td align="left" valign="top">Concern</td><td align="left" valign="top">Hybrid</td><td align="left" valign="top">High</td><td align="left" valign="top">438</td><td align="left" valign="top">297 (67.8)</td><td align="left" valign="top">120 (27.4)</td><td align="left" valign="top">21 (4.8)</td></tr><tr><td align="left" valign="top">Concern</td><td align="left" valign="top">Hybrid</td><td align="left" valign="top">Low</td><td align="left" valign="top">438</td><td align="left" valign="top">246 (56.2)</td><td align="left" valign="top">65 (14.8)</td><td align="left" valign="top">127 (29)</td></tr><tr><td align="left" valign="top">Curiosity</td><td align="left" valign="top">AI</td><td align="left" valign="top">High</td><td align="left" valign="top">441</td><td align="left" valign="top">247 (56)</td><td align="left" valign="top">141 (32)</td><td align="left" valign="top">53 (12)</td></tr><tr><td align="left" valign="top">Curiosity</td><td align="left" valign="top">AI</td><td align="left" valign="top">Low</td><td align="left" valign="top">441</td><td align="left" valign="top">206 (46.7)</td><td align="left" valign="top">94 (21.3)</td><td align="left" valign="top">141 (32)</td></tr><tr><td align="left" valign="top">Curiosity</td><td align="left" valign="top">Hybrid</td><td align="left" valign="top">High</td><td align="left" valign="top">441</td><td align="left" valign="top">281 (63.7)</td><td align="left" valign="top">130 (29.5)</td><td align="left" valign="top">30 (6.8)</td></tr><tr><td align="left" valign="top">Curiosity</td><td align="left" valign="top">Hybrid</td><td align="left" valign="top">Low</td><td align="left" valign="top">441</td><td align="left" valign="top">255 (57.8)</td><td align="left" valign="top">64 (14.5)</td><td align="left" valign="top">122 (27.7)</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p><sup>a</sup>Percentages were calculated within each motivation &#x00D7; source &#x00D7; risk condition.</p></fn></table-wrap-foot></table-wrap><p>In practical terms, individuals driven by concern showed a larger increase in adherence intentions when receiving a high-risk assessment than those driven by curiosity.</p></sec></sec><sec id="s3-4"><title>Sensitivity Analysis</title><sec id="s3-4-1"><title>Overview</title><p>To address the proportional odds assumption violation for risk assessment, 2 binary generalized linear mixed model sensitivity analyses were conducted with the same predictors and participant random intercepts. The first contrasted high adherence intentions vs moderate/neglect; the second contrasted neglect vs high/moderate adherence, reflecting the theoretically motivated distinction between engagement (high and moderate) and disengagement (neglect).</p><p>Main effects replicated across both models: hybrid source increased odds of high adherence intentions (OR 1.45, 95% CI 1.08-1.94; <italic>P</italic>=.01), and high-risk assessment strongly reduced odds of neglect (OR 9.40, 95% CI 6.04-14.63; <italic>P</italic>&#x003C;.001). Critically, the risk &#x00D7; motivation interaction replicated in the neglect model (OR 0.44, 95% CI 0.25-0.78; <italic>P</italic>=.005), confirming that concern-motivated participants were significantly less likely to neglect a high-risk assessment compared to curiosity-motivated participants&#x2014;consistent with the CLMM finding that the boost in adherence intentions from high risk was larger for concern than curiosity. The interaction did not reach significance in the high adherence intentions model (<italic>P</italic>=.11), indicating that the effect is specifically concentrated at the disengagement threshold rather than the high engagement threshold. These analyses confirm that the CLMM findings are robust to the proportional odds violation. The relatively narrow CIs indicate that these effects were estimated with good precision.</p></sec><sec id="s3-4-2"><title>H3: Trust Will Mediate the Effect of Advice Source on Adherence Intentions</title><sec id="s3-4-2-1"><title>CLMM on Adherence Intentions by Trust and Advice Source</title><p>The CLMM&#x2014;with participant as a random intercept&#x2014;showed that greater trust significantly increased odds of stronger adherence intentions. Advice source had no main (<italic>P</italic>=.29) or interaction effect (<italic>P</italic>=.17), indicating trust&#x2019;s influence on adherence intentions was consistent across sources (see <xref ref-type="supplementary-material" rid="app7">Multimedia Appendix 7</xref>). These results suggest that trust mediates advice source&#x2019;s effect on adherence intentions, supporting hypothesis H3, contrasting with H1b where advice source affected adherence when trust was not accounted for.</p></sec><sec id="s3-4-2-2"><title>Mediation Analyses via Monte Carlo Simulation</title><p>The indirect effect of advice source on adherence intentions via trust was estimated as the product of 2 paths: source &#x2192; trust and trust &#x2192; adherence intentions, assessed through a Monte Carlo simulation with 10,000 draws. To obtain unbiased estimates, both CLMM for trust&#x2019;s effect on adherence (path b) and LMM for source&#x2019;s effect on trust (path a) were rerun without any interaction terms. The CLMM showed a statistically significant negative effect of trust on adherence intentions (estimate=&#x2013;0.030, SE =0.002; <italic>P</italic>&#x003C;.001), indicating that higher trust predicted better adherence. The LMM revealed a highly significant and negative effect of AI source compared to the reference hybrid source (estimate=&#x2013;11.20, SE =0.41; <italic>P</italic>&#x003C;.001), indicating lower trust under AI-only advice. Combining these path coefficients, the indirect effect was estimated as 0.34 with a 95% CI (0.29-0.39), excluding zero and indicating good precision as well as full mediation (H3). The relatively narrow CI indicates that this mediated effect was estimated with good precision. This positive indirect effect suggests that hybrid advice sources increase adherence intentions by enhancing trust.</p><p><xref ref-type="fig" rid="figure4">Figure 4</xref> provides an overview of the results of the main hypothesis tests.</p><fig position="float" id="figure4"><label>Figure 4.</label><caption><p>Summary of preregistered hypotheses and main results from the randomized vignette experiment among Dutch adults recruited from the Erasmus MC Patient Panel, Rotterdam, the Netherlands, May to June 2025. Ticks (&#x2714;) indicate hypotheses supported by the evidence.</p></caption><graphic alt-version="no" mimetype="image" position="float" xlink:type="simple" xlink:href="mhealth_v14i1e93991_fig04.png"/></fig></sec></sec></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>This randomized controlled, vignette experiment aimed to answer the question &#x201C;How do advice source (AI alone or Hybrid) and user motivation (curiosity vs concern) shape patient trust and adherence intentions to the provided advice within the context of AI-supported teledermatology?&#x201D; The 879 participating adults reported trusting risk assessments from a hybrid source (AI plus a teledermatologist) more than AI-only assessments and reported higher intentions to follow the advice. Mediation analysis showed that trust fully explained this effect, meaning that hybrid advice increased adherence intentions by increasing the participants&#x2019; trust. A high risk of a malignancy (rather than a low risk) further strengthened the intention to follow the advice, particularly among participants who use the app out of concern rather than out of curiosity. Notably, the sensitivity analysis revealed that the interaction between motivational context and risk assessment level was specific to the disengagement threshold: concern-motivated participants were significantly less likely to neglect a high-risk assessment compared to curiosity-motivated participants, while the 2 groups did not differ substantially in rates of high adherence intentions. This suggests that users motivated by curiosity are more likely to neglect when receiving high-risk assessments, compared to users who are already concerned. From a health behavior perspective, this is consistent with protection motivation theory [<xref ref-type="bibr" rid="ref55">55</xref>], which posits that threat appraisal motivates protective behavior most strongly when perceived vulnerability is high and personally relevant. Curiosity-driven users&#x2014;who may perceive themselves as less personally at risk&#x2014;may be more prone to dismissing unexpected high-risk findings as a false alarm.</p><p>The results also identified trust as the central mechanism through which hybrid advice improves adherence intentions, highlighting the value of integrating teledermatologist supervision into AI-driven skin cancer apps to maximize triaging efficiency. An overview of the main results can be found in <xref ref-type="fig" rid="figure4">Figure 4</xref>. Our findings differ slightly from those of Soellner and Koenigstorfer [<xref ref-type="bibr" rid="ref56">56</xref>], who found that the mediators between increased patient compliance and human physician supplementing AI were perceived social presence and innovativeness, suggesting multiple mediating factors are induced by human clinician presence. Similarly, Reis et al [<xref ref-type="bibr" rid="ref57">57</xref>] found patients preferred human-only chat responses for reliability, empathy, and willingness to follow advice, compared with an AI chatbot or a hybrid chat. Soellner and Koenigstorfer [<xref ref-type="bibr" rid="ref56">56</xref>] presented AI in a positive manner and communicated a clear purpose, mentioning AI&#x2019;s capability in diagnosing skin lesion photos. In contrast, Reis et al [<xref ref-type="bibr" rid="ref57">57</xref>] used chatbot transcripts without clarifying AI&#x2019;s role, possibly explaining the preference for human-only advice rather than hybrid. These findings suggest hybrid advice works best when users understand the AI&#x2019;s purpose, not as a full substitute for human care [<xref ref-type="bibr" rid="ref58">58</xref>]. Therefore, it is recommended to ensure patients understand the purpose of AI&#x2019;s involvement, alleviating patients&#x2019; concerns about losing human involvement in health care [<xref ref-type="bibr" rid="ref59">59</xref>], and for making human-AI collaboration more effective.</p></sec><sec id="s4-2"><title>Practical Implications</title><p>Although including a human teledermatologist was found to increase the likelihood of higher adherence intentions by a factor of 1.7, and users&#x2019; trust in the assessment from 66% to 77%, always including human teledermatologist supervision may be increasing workload too much [<xref ref-type="bibr" rid="ref26">26</xref>]. Both AI-alone and hybrid models are more cost-effective postreferral than face-to-face assessments without AI [<xref ref-type="bibr" rid="ref26">26</xref>], but only offering teledermatology to cases where the AI assessment is high risk, or shifting the usage of AI to postreferral by a primary health care provider, may be an effective compromise, depending on the intervention requirements and goals. This is particularly relevant given that Smak Gregoor et al [<xref ref-type="bibr" rid="ref30">30</xref>] found that low-risk app assessments failed to prevent unnecessary appointments, tripling benign lesion claims. Offering teledermatology review to concerned users with low-risk assessments may be a strategy to prevent in-person appointments, depending on the health care system. To avoid users neglecting high-risk assessments, strategies are required to ensure that those who use the app out of curiosity take the assessment seriously. High-risk assessments may require tailored messaging for users who do not present with preexisting concern, to prevent disengagement in precisely the cases where action is most warranted.</p></sec><sec id="s4-3"><title>Strengths and Limitations</title><p>Our study provides insights on intended adherence to low-risk/benign assessments&#x2014;reflecting most real-world cases&#x2014;rather than comparing stage 0 skin cancer with stage 2 as did Soellner and Koenigstorfer [<xref ref-type="bibr" rid="ref56">56</xref>], which represents the minority of cases. Thus, our results provide insights into drivers of patients&#x2019; adherence intentions prior to triaging, which is crucial for avoiding overdiagnosis [<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref30">30</xref>]. It is worthy of noting that the vignettes in our study altered the motivation (curiosity vs concern), which is intertwined with perceived lesion risk. This was done intentionally to create credible vignettes. However, it is plausible that a user of an app has low perceived lesion risk and is not curious but is using the app for other reasons. Further research could investigate whether using the app because it was encouraged by a family doctor, or family member, or for any other reason influences adherence to the app&#x2019;s advice.</p><p>Our study did not consider costs of teledermatology integration, so AI-only solutions may be more cost-effective despite lower adherence intentions and trust although hybrid solutions appear to be most effective postreferral [<xref ref-type="bibr" rid="ref26">26</xref>]. The study sample was drawn from the Erasmus MC Patient Panel, representing highly engaged health care users with typically higher digital literacy and education levels than in the general population, which may limit generalizability.</p><p>The vignette-based experiment involved participants experiencing hypothetical scenarios, and stated trust and adherence intentions may not fully reflect behavior during actual app use. The use of predetermined simulated app outputs rather than participant-uploaded images prioritizes internal validity by isolating the effects of advice source and risk level, though it may reduce perceived personal relevance compared to a real app scenario. However, vignette responses have been shown to correspond closely with real clinical behavior [<xref ref-type="bibr" rid="ref60">60</xref>], and relative comparisons between conditions are generally robust to hypothetical bias [<xref ref-type="bibr" rid="ref61">61</xref>,<xref ref-type="bibr" rid="ref62">62</xref>]. The mixed design&#x2014;with motivational context as a between-participants factor and advice source and risk level as within-participants factors&#x2014;allowed for controlled manipulation of key variables while accounting for individual differences. The crossover design used randomized trial order, meaning each condition appeared first equally often across participants, so any contrast effects would be unsystematic and unlikely to bias results in a particular direction. Nonetheless, the possibility that participants compared conditions rather than evaluating each independently remains a limitation inherent to within-participants designs, and trust and adherence may further differ when participants submit an actual image and perceive the assessment as personally relevant to their own lesion. Trust was measured using a single-item slider, which, while practical for repeated trial-level measurement, cannot capture the multidimensional nature of trust. Although single-item trust measures have been shown to produce reliable and valid results comparable to multi-item scales [<xref ref-type="bibr" rid="ref47">47</xref>], a validated instrument such as the 11-item Trust in Physician Scale by Thom et al [<xref ref-type="bibr" rid="ref63">63</xref>] may have revealed differential effects of advice source on specific facets of trust&#x2014;such as perceived competence or benevolence&#x2014;rather than on overall trust judgments alone [<xref ref-type="bibr" rid="ref34">34</xref>]. Administering such a scale after each of 4 trials would, however, have imposed considerable respondent burden. Future research could use multi-item trust scales in a between-participants design to examine this more comprehensively.</p></sec><sec id="s4-4"><title>Conclusions</title><p>The findings of this preregistered online experiment support the hypothesis that adding hybrid (teledermatologist and AI) advice increases trust, which, in turn, improves intended adherence, particularly for high-risk assessments and concerned users. This study is innovative in testing teledermatologist supervision in a population-level AI skin cancer app and in examining how motivational context shapes responses to advice. It differs from existing studies focused on postreferral teledermatology [<xref ref-type="bibr" rid="ref26">26</xref>] or chatbot-based advice [<xref ref-type="bibr" rid="ref38">38</xref>] by isolating the effect of hybrid AI-human advice in a store-and-forward screening context. These findings can inform the design of AI-based health care apps such that maximal triaging efficiency is achieved. Practically, these results support consideration of teledermatologist supervision in AI-based triage systems where maximizing trust, adherence, and safe follow-through are priorities.</p></sec></sec></body><back><ack><p>The authors would like to thank Mr Christos Diamantidis, MD, for his advice on the coding of the adherence intention answer options, as described in <xref ref-type="table" rid="table1">Table 1</xref>. The data were obtained through the Erasmus MC Patient Panel [<xref ref-type="bibr" rid="ref43">43</xref>] (quality instrument), organized by the Directorate of Quality &#x0026; Patient Care of Erasmus Medical Centre.</p></ack><notes><sec><title>Generative AI Use</title><p>According to the GAIDeT taxonomy (2025), the following tasks were delegated to GenAI tools under full human supervision: code generation, code optimization, data cleaning, data curation and organization, data analysis, visualization, proofreading and editing, formulation of conclusions, and translation. The GenAI tool used was Perplexity, which uses a variety of models, and ChatGPT 5.6 Terra. Responsibility for the final manuscript lies entirely with the authors. GenAI tools are not listed as authors and do not bear responsibility for the final outcomes. Declaration submitted by RS, MM</p></sec><sec><title>Funding</title><p>This work was supported by the Netherlands Organisation for Health Research and Development (ZonMw) through a Vidi grant (grant number 09150172210015) awarded to LZ.</p></sec><sec><title>Data Availability</title><p>Data used in this study are available upon request&#x2014;please contact secretariaat.mgz@erasmusmc.nl. The available data include (1) the Qualtrics printout PDF, (2) R and SPSS analysis codes, and (3) the anonymized dataset.</p></sec></notes><fn-group><fn fn-type="con"><p>Conceptualization: RS, MM, LZ</p><p>Data curation: RS, MM</p><p>Formal analysis: RS, MM</p><p>Funding acquisition: LZ</p><p>Methodology: RS, MM, LZ</p><p>Project administration: ND, EB</p><p>Resources: ND, EB</p><p>Supervision: JS, MW, LZ</p><p>Visualization: RS</p><p>Writing &#x2013; original draft: RS, MM</p><p>Writing &#x2013; review &#x0026; editing: RS, JS, MW, LZ</p></fn><fn fn-type="conflict"><p>The Department of Dermatology of the Erasmus MC Cancer Institute, where MW is affiliated, has received an unrestricted research grant from SkinVision. The remaining authors declare no conflicts of interest.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">AIAS-4</term><def><p>4-item AI Attitude Scale</p></def></def-item><def-item><term id="abb2">CLMM</term><def><p>cumulative link mixed model</p></def></def-item><def-item><term id="abb3">CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term id="abb4">CONSORT-EHEALTH</term><def><p>Consolidated Standards of Reporting Trials of Electronic and Mobile Health Applications and Online Telehealth</p></def></def-item><def-item><term id="abb5">LMM</term><def><p>linear mixed-effect model</p></def></def-item><def-item><term id="abb6">OR</term><def><p>odds ratio</p></def></def-item><def-item><term id="abb7">TIDieR</term><def><p>Template for Intervention Description and Replication</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whiteman</surname><given-names>DC</given-names> </name><name name-style="western"><surname>Green</surname><given-names>AC</given-names> </name><name name-style="western"><surname>Olsen</surname><given-names>CM</given-names> </name></person-group><article-title>The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031</article-title><source>J Invest Dermatol</source><year>2016</year><month>06</month><volume>136</volume><issue>6</issue><fpage>1161</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2016.01.035</pub-id><pub-id pub-id-type="medline">26902923</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roky</surname><given-names>AH</given-names> </name><name name-style="western"><surname>Islam</surname><given-names>MM</given-names> </name><name name-style="western"><surname>Ahasan</surname><given-names>AMF</given-names> </name><etal/></person-group><article-title>Overview of skin cancer types and prevalence rates across continents</article-title><source>Cancer Pathog Ther</source><year>2025</year><volume>3</volume><issue>2</issue><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.cpt.2024.08.002</pub-id><pub-id pub-id-type="medline">40182119</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saginala</surname><given-names>K</given-names> </name><name name-style="western"><surname>Barsouk</surname><given-names>A</given-names> </name><name name-style="western"><surname>Aluru</surname><given-names>JS</given-names> </name><name name-style="western"><surname>Rawla</surname><given-names>P</given-names> </name><name name-style="western"><surname>Barsouk</surname><given-names>A</given-names> </name></person-group><article-title>Epidemiology of melanoma</article-title><source>Med Sci (Basel)</source><year>2021</year><month>10</month><day>20</day><volume>9</volume><issue>4</issue><fpage>63</fpage><pub-id pub-id-type="doi">10.3390/medsci9040063</pub-id><pub-id pub-id-type="medline">34698235</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lomas</surname><given-names>A</given-names> </name><name name-style="western"><surname>Leonardi-Bee</surname><given-names>J</given-names> </name><name name-style="western"><surname>Bath-Hextall</surname><given-names>F</given-names> </name></person-group><article-title>A systematic review of worldwide incidence of nonmelanoma skin cancer</article-title><source>Br J Dermatol</source><year>2012</year><month>05</month><volume>166</volume><issue>5</issue><fpage>1069</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.10830.x</pub-id><pub-id pub-id-type="medline">22251204</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>K</given-names> </name><name name-style="western"><surname>Mehrmal</surname><given-names>S</given-names> </name><name name-style="western"><surname>Uppal</surname><given-names>P</given-names> </name><name name-style="western"><surname>Giesey</surname><given-names>RL</given-names> </name><name name-style="western"><surname>Delost</surname><given-names>GR</given-names> </name></person-group><article-title>The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990-2017</article-title><source>JAAD Int</source><year>2021</year><month>03</month><volume>2</volume><fpage>98</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.jdin.2020.10.013</pub-id><pub-id pub-id-type="medline">34409358</pub-id></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnold</surname><given-names>M</given-names> </name><name name-style="western"><surname>Singh</surname><given-names>D</given-names> </name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names> </name><etal/></person-group><article-title>Global burden of cutaneous melanoma in 2020 and projections to 2040</article-title><source>JAMA Dermatol</source><year>2022</year><month>05</month><day>1</day><volume>158</volume><issue>5</issue><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2022.0160</pub-id><pub-id pub-id-type="medline">35353115</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names> </name><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Han</surname><given-names>L</given-names> </name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Wan</surname><given-names>M</given-names> </name></person-group><article-title>Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990-2021</article-title><source>Sci Rep</source><year>2025</year><month>02</month><day>18</day><volume>15</volume><issue>1</issue><fpage>5996</fpage><pub-id pub-id-type="doi">10.1038/s41598-025-90485-3</pub-id><pub-id pub-id-type="medline">39966563</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tommasino</surname><given-names>N</given-names> </name><name name-style="western"><surname>Megna</surname><given-names>M</given-names> </name><name name-style="western"><surname>Cacciapuoti</surname><given-names>S</given-names> </name><etal/></person-group><article-title>The past, the present and the future of teledermatology: a narrative review</article-title><source>Clin Cosmet Investig Dermatol</source><year>2024</year><volume>17</volume><fpage>717</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.2147/CCID.S462799</pub-id><pub-id pub-id-type="medline">38529172</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zakaria</surname><given-names>A</given-names> </name><name name-style="western"><surname>Miclau</surname><given-names>TA</given-names> </name><name name-style="western"><surname>Maurer</surname><given-names>T</given-names> </name><name name-style="western"><surname>Leslie</surname><given-names>KS</given-names> </name><name name-style="western"><surname>Amerson</surname><given-names>E</given-names> </name></person-group><article-title>Cost minimization analysis of a teledermatology triage system in a managed care setting</article-title><source>JAMA Dermatol</source><year>2021</year><month>01</month><day>1</day><volume>157</volume><issue>1</issue><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2020.4066</pub-id><pub-id pub-id-type="medline">33206146</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drabarek</surname><given-names>D</given-names> </name><name name-style="western"><surname>Habgood</surname><given-names>E</given-names> </name><name name-style="western"><surname>Ackermann</surname><given-names>D</given-names> </name><etal/></person-group><article-title>Perspectives and experiences of patient-led melanoma surveillance using digital technologies from clinicians involved in the MEL-SELF pilot randomized controlled trial: qualitative interview study</article-title><source>JMIR Dermatol</source><year>2022</year><month>12</month><day>20</day><volume>5</volume><issue>4</issue><fpage>e40623</fpage><pub-id pub-id-type="doi">10.2196/40623</pub-id><pub-id pub-id-type="medline">37632906</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ijaz</surname><given-names>M</given-names> </name></person-group><article-title>BT01 The effectiveness of telemedicine in dermatology services: a systematic review</article-title><source>Br J Dermatol</source><year>2025</year><volume>193</volume><issue>Supplement_1</issue><pub-id pub-id-type="doi">10.1093/bjd/ljaf085.526</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidal-Alaball</surname><given-names>J</given-names> </name><name name-style="western"><surname>Garcia Domingo</surname><given-names>JL</given-names> </name><name name-style="western"><surname>Garcia Cuy&#x00E0;s</surname><given-names>F</given-names> </name><etal/></person-group><article-title>A cost savings analysis of asynchronous teledermatology compared to face-to-face dermatology in Catalonia</article-title><source>BMC Health Serv Res</source><year>2018</year><month>08</month><day>22</day><volume>18</volume><issue>1</issue><fpage>650</fpage><pub-id pub-id-type="doi">10.1186/s12913-018-3464-4</pub-id><pub-id pub-id-type="medline">30134891</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smak Gregoor</surname><given-names>AM</given-names> </name><name name-style="western"><surname>Sangers</surname><given-names>TE</given-names> </name><name name-style="western"><surname>Eekhof</surname><given-names>JA</given-names> </name><etal/></person-group><article-title>Artificial intelligence in mobile health for skin cancer diagnostics at home (AIM HIGH): a pilot feasibility study</article-title><source>EClinicalMedicine</source><year>2023</year><volume>60</volume><fpage>102019</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102019</pub-id><pub-id pub-id-type="medline">37261324</pub-id></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trakatelli</surname><given-names>M</given-names> </name><name name-style="western"><surname>Siskou</surname><given-names>S</given-names> </name><name name-style="western"><surname>Proby</surname><given-names>C</given-names> </name><etal/></person-group><article-title>The patient journey: a report of skin cancer care across Europe</article-title><source>Br J Dermatol</source><year>2012</year><month>08</month><volume>167 Suppl 2</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2012.11086.x</pub-id><pub-id pub-id-type="medline">22881587</pub-id></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balboul</surname><given-names>S</given-names> </name><name name-style="western"><surname>Gronbeck</surname><given-names>C</given-names> </name><name name-style="western"><surname>Feng</surname><given-names>H</given-names> </name></person-group><article-title>Dermatology workforce projections in the United States, 2021 to 2036</article-title><source>Arch Dermatol Res</source><year>2024</year><month>05</month><day>22</day><volume>316</volume><issue>5</issue><fpage>192</fpage><pub-id pub-id-type="doi">10.1007/s00403-024-02924-2</pub-id><pub-id pub-id-type="medline">38775980</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>M</given-names> </name><name name-style="western"><surname>Burshtein</surname><given-names>J</given-names> </name><name name-style="western"><surname>Zakria</surname><given-names>D</given-names> </name><name name-style="western"><surname>Rigel</surname><given-names>D</given-names> </name></person-group><article-title>Analysis of trends in US dermatologist density and geographic distribution</article-title><source>J Am Acad Dermatol</source><year>2024</year><month>08</month><volume>91</volume><issue>2</issue><fpage>338</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2024.03.037</pub-id><pub-id pub-id-type="medline">38574771</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talebi-Liasi</surname><given-names>F</given-names> </name><name name-style="western"><surname>Markowitz</surname><given-names>O</given-names> </name></person-group><article-title>Is artificial intelligence going to replace dermatologists?</article-title><source>Cutis</source><year>2020</year><month>01</month><volume>105</volume><issue>1</issue><fpage>28</fpage><lpage>31</lpage><pub-id pub-id-type="medline">32074153</pub-id></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Koban</surname><given-names>KC</given-names> </name><name name-style="western"><surname>Schenck</surname><given-names>TL</given-names> </name><name name-style="western"><surname>Giunta</surname><given-names>RE</given-names> </name><name name-style="western"><surname>Li</surname><given-names>Q</given-names> </name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names> </name></person-group><article-title>Artificial intelligence in dermatology image analysis: current developments and future trends</article-title><source>J Clin Med</source><year>2022</year><month>11</month><day>18</day><volume>11</volume><issue>22</issue><fpage>6826</fpage><pub-id pub-id-type="doi">10.3390/jcm11226826</pub-id><pub-id pub-id-type="medline">36431301</pub-id></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>BCW</given-names> </name><name name-style="western"><surname>Flaherty</surname><given-names>G</given-names> </name></person-group><article-title>Artificial intelligence in dermatology: are we there yet?</article-title><source>Br J Dermatol</source><year>2019</year><month>07</month><volume>181</volume><issue>1</issue><fpage>190</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1111/bjd.17899</pub-id><pub-id pub-id-type="medline">30912580</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salinas</surname><given-names>MP</given-names> </name><name name-style="western"><surname>Sep&#x00FA;lveda</surname><given-names>J</given-names> </name><name name-style="western"><surname>Hidalgo</surname><given-names>L</given-names> </name><etal/></person-group><article-title>A systematic review and meta-analysis of artificial intelligence versus clinicians for skin cancer diagnosis</article-title><source>NPJ Digit Med</source><year>2024</year><month>05</month><day>14</day><volume>7</volume><issue>1</issue><fpage>125</fpage><pub-id pub-id-type="doi">10.1038/s41746-024-01103-x</pub-id><pub-id pub-id-type="medline">38744955</pub-id></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>S</given-names> </name><name name-style="western"><surname>Achar</surname><given-names>U</given-names> </name><name name-style="western"><surname>Hakim</surname><given-names>B</given-names> </name><name name-style="western"><surname>Achar</surname><given-names>A</given-names> </name></person-group><article-title>Artificial intelligence in dermatology: a systematized review</article-title><source>Int J Dermatol Venereol</source><year>2025</year><volume>8</volume><issue>1</issue><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1097/JD9.0000000000000404</pub-id></nlm-citation></ref><ref id="ref22"><label>22</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du-Harpur</surname><given-names>X</given-names> </name><name name-style="western"><surname>Watt</surname><given-names>FM</given-names> </name><name name-style="western"><surname>Luscombe</surname><given-names>NM</given-names> </name><name name-style="western"><surname>Lynch</surname><given-names>MD</given-names> </name></person-group><article-title>What is AI? Applications of artificial intelligence to dermatology</article-title><source>Br J Dermatol</source><year>2020</year><month>09</month><volume>183</volume><issue>3</issue><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1111/bjd.18880</pub-id><pub-id pub-id-type="medline">31960407</pub-id></nlm-citation></ref><ref id="ref23"><label>23</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goessinger</surname><given-names>EV</given-names> </name><name name-style="western"><surname>Niederfeilner</surname><given-names>JC</given-names> </name><name name-style="western"><surname>Cerminara</surname><given-names>S</given-names> </name><etal/></person-group><article-title>Patient and dermatologists&#x2019; perspectives on augmented intelligence for melanoma screening: a prospective study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2024</year><month>12</month><volume>38</volume><issue>12</issue><fpage>2240</fpage><lpage>2249</lpage><pub-id pub-id-type="doi">10.1111/jdv.19905</pub-id><pub-id pub-id-type="medline">38411348</pub-id></nlm-citation></ref><ref id="ref24"><label>24</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuppanda</surname><given-names>PM</given-names> </name><name name-style="western"><surname>Janda</surname><given-names>M</given-names> </name><name name-style="western"><surname>Soyer</surname><given-names>HP</given-names> </name><name name-style="western"><surname>Caffery</surname><given-names>LJ</given-names> </name></person-group><article-title>What are patients&#x2019; perceptions and attitudes regarding the use of artificial intelligence in skin cancer screening and diagnosis? Narrative review</article-title><source>J Invest Dermatol</source><year>2025</year><month>08</month><volume>145</volume><issue>8</issue><fpage>1858</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2025.01.013</pub-id><pub-id pub-id-type="medline">40019459</pub-id></nlm-citation></ref><ref id="ref25"><label>25</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mevorach</surname><given-names>L</given-names> </name><name name-style="western"><surname>Farcomeni</surname><given-names>A</given-names> </name><name name-style="western"><surname>Pellacani</surname><given-names>G</given-names> </name><name name-style="western"><surname>Cantisani</surname><given-names>C</given-names> </name></person-group><article-title>A comparison of skin lesions&#x2019; diagnoses between AI-based image classification, an expert dermatologist, and a non-expert</article-title><source>Diagnostics (Basel)</source><year>2025</year><month>04</month><day>28</day><volume>15</volume><issue>9</issue><fpage>1115</fpage><pub-id pub-id-type="doi">10.3390/diagnostics15091115</pub-id><pub-id pub-id-type="medline">40361933</pub-id></nlm-citation></ref><ref id="ref26"><label>26</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhelev</surname><given-names>Z</given-names> </name><name name-style="western"><surname>Puttergill</surname><given-names>D</given-names> </name><name name-style="western"><surname>Kalsi</surname><given-names>D</given-names> </name><name name-style="western"><surname>Mullarkey</surname><given-names>D</given-names> </name><name name-style="western"><surname>Hyde</surname><given-names>C</given-names> </name></person-group><article-title>BT29 Modelling the cost-effectiveness of an artificial intelligence as a medical device</article-title><source>Br J Dermatol</source><year>2024</year><month>06</month><day>28</day><volume>191</volume><issue>Supplement_1</issue><fpage>i202</fpage><pub-id pub-id-type="doi">10.1093/bjd/ljae090.426</pub-id></nlm-citation></ref><ref id="ref27"><label>27</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giansanti</surname><given-names>D</given-names> </name></person-group><article-title>The artificial intelligence in teledermatology: a narrative review on opportunities, perspectives, and bottlenecks</article-title><source>Int J Environ Res Public Health</source><year>2023</year><month>05</month><day>12</day><volume>20</volume><issue>10</issue><fpage>5810</fpage><pub-id pub-id-type="doi">10.3390/ijerph20105810</pub-id><pub-id pub-id-type="medline">37239537</pub-id></nlm-citation></ref><ref id="ref28"><label>28</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sangers</surname><given-names>T</given-names> </name><name name-style="western"><surname>Reeder</surname><given-names>S</given-names> </name><name name-style="western"><surname>van der Vet</surname><given-names>S</given-names> </name><etal/></person-group><article-title>Validation of a market-approved artificial intelligence mobile health app for skin cancer screening: a prospective multicenter diagnostic accuracy study</article-title><source>Dermatology</source><year>2022</year><volume>238</volume><issue>4</issue><fpage>649</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1159/000520474</pub-id><pub-id pub-id-type="medline">35124665</pub-id></nlm-citation></ref><ref id="ref29"><label>29</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greis</surname><given-names>C</given-names> </name><name name-style="western"><surname>Maul</surname><given-names>LV</given-names> </name><name name-style="western"><surname>Hsu</surname><given-names>C</given-names> </name><name name-style="western"><surname>Djamei</surname><given-names>V</given-names> </name><name name-style="western"><surname>Schmid-Grendelmeier</surname><given-names>P</given-names> </name><name name-style="western"><surname>Navarini</surname><given-names>AA</given-names> </name></person-group><article-title>Artificial intelligence to support telemedicine in Africa [Article in German]</article-title><source>Hautarzt</source><year>2020</year><month>09</month><volume>71</volume><issue>9</issue><fpage>686</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1007/s00105-020-04664-6</pub-id><pub-id pub-id-type="medline">32761386</pub-id></nlm-citation></ref><ref id="ref30"><label>30</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smak Gregoor</surname><given-names>AM</given-names> </name><name name-style="western"><surname>Sangers</surname><given-names>TE</given-names> </name><name name-style="western"><surname>Bakker</surname><given-names>LJ</given-names> </name><etal/></person-group><article-title>An artificial intelligence based app for skin cancer detection evaluated in a population based setting</article-title><source>NPJ Digit Med</source><year>2023</year><month>05</month><day>20</day><volume>6</volume><issue>1</issue><fpage>90</fpage><pub-id pub-id-type="doi">10.1038/s41746-023-00831-w</pub-id><pub-id pub-id-type="medline">37210466</pub-id></nlm-citation></ref><ref id="ref31"><label>31</label><nlm-citation citation-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Champion</surname><given-names>VL</given-names> </name><name name-style="western"><surname>Skinner</surname><given-names>CS</given-names> </name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Glanz</surname><given-names>K</given-names></name><name name-style="western"><surname>Rimer</surname><given-names>BK</given-names></name><name name-style="western"><surname>Viswanath</surname><given-names>K</given-names></name></person-group><article-title>The health belief model</article-title><source>Health Behavior and Health Education: Theory, Research, and Practice</source><year>2008</year><edition>4</edition><publisher-name>Jossey-Bass</publisher-name><fpage>45</fpage><lpage>65</lpage><pub-id pub-id-type="other">9780787996147</pub-id></nlm-citation></ref><ref id="ref32"><label>32</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names> </name><name name-style="western"><surname>Liao</surname><given-names>M</given-names> </name><name name-style="western"><surname>Walther</surname><given-names>JB</given-names> </name><name name-style="western"><surname>Sundar</surname><given-names>SS</given-names> </name></person-group><article-title>When an AI doctor gets personal: the effects of social and medical individuation in encounters with human and AI doctors</article-title><source>Communic Res</source><year>2024</year><month>10</month><volume>51</volume><issue>7</issue><fpage>747</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1177/00936502241263482</pub-id></nlm-citation></ref><ref id="ref33"><label>33</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horn</surname><given-names>S</given-names> </name><name name-style="western"><surname>Litovsky</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Loewenstein</surname><given-names>G</given-names> </name></person-group><article-title>Using curiosity to counter health information avoidance</article-title><source>Soc Sci Med</source><year>2024</year><month>01</month><volume>340</volume><fpage>116383</fpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2023.116383</pub-id><pub-id pub-id-type="medline">38039766</pub-id></nlm-citation></ref><ref id="ref34"><label>34</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozawa</surname><given-names>S</given-names> </name><name name-style="western"><surname>Sripad</surname><given-names>P</given-names> </name></person-group><article-title>How do you measure trust in the health system? A systematic review of the literature</article-title><source>Soc Sci Med</source><year>2013</year><month>08</month><volume>91</volume><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2013.05.005</pub-id><pub-id pub-id-type="medline">23849233</pub-id></nlm-citation></ref><ref id="ref35"><label>35</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>RW</given-names> </name><name name-style="western"><surname>Head</surname><given-names>AJ</given-names> </name><name name-style="western"><surname>Ren&#x00E9;</surname><given-names>J</given-names> </name><etal/></person-group><article-title>Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician</article-title><source>J Rheumatol</source><year>2008</year><month>04</month><volume>35</volume><issue>4</issue><fpage>618</fpage><lpage>624</lpage><pub-id pub-id-type="medline">18278840</pub-id></nlm-citation></ref><ref id="ref36"><label>36</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names> </name><name name-style="western"><surname>Lowry</surname><given-names>PB</given-names> </name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names> </name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names> </name></person-group><article-title>Patient trust in physicians matters-understanding the role of a mobile patient education system and patient-physician communication in improving patient adherence behavior: field study</article-title><source>J Med Internet Res</source><year>2022</year><month>12</month><day>20</day><volume>24</volume><issue>12</issue><fpage>e42941</fpage><pub-id pub-id-type="doi">10.2196/42941</pub-id><pub-id pub-id-type="medline">36538351</pub-id></nlm-citation></ref><ref id="ref37"><label>37</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Y</given-names> </name><name name-style="western"><surname>Guan</surname><given-names>S</given-names> </name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names> </name><etal/></person-group><article-title>Effects of the two-dimensional structure of trust on patient adherence to medication and non-pharmaceutical treatment: a cross-sectional study of rural patients with essential hypertension in China</article-title><source>Front Public Health</source><year>2022</year><volume>10</volume><fpage>818426</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.818426</pub-id><pub-id pub-id-type="medline">35309202</pub-id></nlm-citation></ref><ref id="ref38"><label>38</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riedl</surname><given-names>R</given-names> </name><name name-style="western"><surname>Hogeterp</surname><given-names>SA</given-names> </name><name name-style="western"><surname>Reuter</surname><given-names>M</given-names> </name></person-group><article-title>Do patients prefer a human doctor, artificial intelligence, or a blend, and is this preference dependent on medical discipline? Empirical evidence and implications for medical practice</article-title><source>Front Psychol</source><year>2024</year><volume>15</volume><fpage>1422177</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2024.1422177</pub-id><pub-id pub-id-type="medline">39188871</pub-id></nlm-citation></ref><ref id="ref39"><label>39</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>RH</given-names> </name><name name-style="western"><surname>Barbieri</surname><given-names>JS</given-names> </name><name name-style="western"><surname>Nguyen</surname><given-names>HP</given-names> </name><etal/></person-group><article-title>Clinical effectiveness and cost-effectiveness of teledermatology: where are we now, and what are the barriers to adoption?</article-title><source>J Am Acad Dermatol</source><year>2020</year><month>07</month><volume>83</volume><issue>1</issue><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2020.01.065</pub-id><pub-id pub-id-type="medline">32035106</pub-id></nlm-citation></ref><ref id="ref40"><label>40</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>SC</given-names> </name><name name-style="western"><surname>Roberts</surname><given-names>MC</given-names> </name><name name-style="western"><surname>Keeley</surname><given-names>JW</given-names> </name><etal/></person-group><article-title>Vignette methodologies for studying clinicians&#x2019; decision-making: validity, utility, and application in ICD-11 field studies</article-title><source>Int J Clin Health Psychol</source><year>2015</year><volume>15</volume><issue>2</issue><fpage>160</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.ijchp.2014.12.001</pub-id><pub-id pub-id-type="medline">30487833</pub-id></nlm-citation></ref><ref id="ref41"><label>41</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faul</surname><given-names>F</given-names> </name><name name-style="western"><surname>Erdfelder</surname><given-names>E</given-names> </name><name name-style="western"><surname>Lang</surname><given-names>AG</given-names> </name><name name-style="western"><surname>Buchner</surname><given-names>A</given-names> </name></person-group><article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behav Res Methods</source><year>2007</year><month>05</month><volume>39</volume><issue>2</issue><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/bf03193146</pub-id><pub-id pub-id-type="medline">17695343</pub-id></nlm-citation></ref><ref id="ref42"><label>42</label><nlm-citation citation-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J</given-names> </name></person-group><source>Statistical Power Analysis for the Behavioral Sciences</source><year>1988</year><edition>2</edition><publisher-name>Lawrence Erlbaum Associates</publisher-name><pub-id pub-id-type="other">9780203771587</pub-id></nlm-citation></ref><ref id="ref43"><label>43</label><nlm-citation citation-type="web"><article-title>Digitale pati&#x00EB;ntpanel [Article in Dutch]</article-title><source>Erasmus MC</source><access-date>2026-10-27</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.erasmusmc.nl/nl-nl/uw-mening-telt/patientpanel">https://www.erasmusmc.nl/nl-nl/uw-mening-telt/patientpanel</ext-link></comment></nlm-citation></ref><ref id="ref44"><label>44</label><nlm-citation citation-type="web"><article-title>Clinical trials</article-title><source>ICMJE (International Committee of Medical Journal Editors)</source><year>2026</year><access-date>2026-10-27</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html</ext-link></comment></nlm-citation></ref><ref id="ref45"><label>45</label><nlm-citation citation-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Swain</surname><given-names>R</given-names> </name><name name-style="western"><surname>Zwaan</surname><given-names>L</given-names> </name><name name-style="western"><surname>Masic</surname><given-names>M</given-names> </name></person-group><article-title>Influence of teledermatologist supervision on patient trust and adherence in an AI-driven dermatology app: a randomised-controlled experiment</article-title><source>OSF (Open Science Framework)</source><year>2025</year><access-date>2026-10-27</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://osf.io/64pjn/overview">https://osf.io/64pjn/overview</ext-link></comment></nlm-citation></ref><ref id="ref46"><label>46</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grassini</surname><given-names>S</given-names> </name></person-group><article-title>Development and validation of the AI Attitude Scale (AIAS-4): a brief measure of general attitude toward artificial intelligence</article-title><source>Front Psychol</source><year>2023</year><volume>14</volume><fpage>1191628</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2023.1191628</pub-id><pub-id pub-id-type="medline">37554139</pub-id></nlm-citation></ref><ref id="ref47"><label>47</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro</surname><given-names>MS</given-names> </name><name name-style="western"><surname>Bahli</surname><given-names>B</given-names> </name><name name-style="western"><surname>Ferreira</surname><given-names>JJ</given-names> </name><name name-style="western"><surname>Figueiredo</surname><given-names>R</given-names> </name></person-group><article-title>Comparing single-item and multi-item trust scales: insights for assessing trust in project leaders</article-title><source>Behav Sci (Basel)</source><year>2023</year><month>09</month><day>21</day><volume>13</volume><issue>9</issue><fpage>786</fpage><pub-id pub-id-type="doi">10.3390/bs13090786</pub-id><pub-id pub-id-type="medline">37754064</pub-id></nlm-citation></ref><ref id="ref48"><label>48</label><nlm-citation citation-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>RHB</given-names> </name></person-group><article-title>Cumulative link models for ordinal regression with the r package ordinal</article-title><source>R Project</source><year>2018</year><access-date>2026-11-12</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://cloud.r-project.org/web/packages/ordinal/vignettes/clm_article.pdf">https://cloud.r-project.org/web/packages/ordinal/vignettes/clm_article.pdf</ext-link></comment></nlm-citation></ref><ref id="ref49"><label>49</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedeker</surname><given-names>D</given-names> </name><name name-style="western"><surname>Gibbons</surname><given-names>RD</given-names> </name></person-group><article-title>A random-effects ordinal regression model for multilevel analysis</article-title><source>Biometrics</source><year>1994</year><month>12</month><volume>50</volume><issue>4</issue><fpage>933</fpage><lpage>944</lpage><pub-id pub-id-type="medline">7787006</pub-id></nlm-citation></ref><ref id="ref50"><label>50</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopewell</surname><given-names>S</given-names> </name><name name-style="western"><surname>Chan</surname><given-names>AW</given-names> </name><name name-style="western"><surname>Collins</surname><given-names>GS</given-names> </name><etal/></person-group><article-title>CONSORT 2025 statement: updated guideline for reporting randomised trials</article-title><source>Lancet</source><year>2025</year><month>04</month><day>14</day><volume>405</volume><issue>10489</issue><fpage>1633</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(25)00672-5</pub-id><pub-id pub-id-type="medline">40245901</pub-id></nlm-citation></ref><ref id="ref51"><label>51</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopewell</surname><given-names>S</given-names> </name><name name-style="western"><surname>Clarke</surname><given-names>M</given-names> </name><name name-style="western"><surname>Moher</surname><given-names>D</given-names> </name><etal/></person-group><article-title>CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration</article-title><source>PLoS Med</source><year>2008</year><month>01</month><day>22</day><volume>5</volume><issue>1</issue><fpage>e20</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0050020</pub-id><pub-id pub-id-type="medline">18215107</pub-id></nlm-citation></ref><ref id="ref52"><label>52</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eysenbach</surname><given-names>G</given-names> </name><collab>CONSORT-EHEALTH Group</collab></person-group><article-title>CONSORT-EHEALTH: improving and standardizing evaluation reports of web-based and mobile health interventions</article-title><source>J Med Internet Res</source><year>2011</year><month>12</month><day>31</day><volume>13</volume><issue>4</issue><fpage>e126</fpage><pub-id pub-id-type="doi">10.2196/jmir.1923</pub-id><pub-id pub-id-type="medline">22209829</pub-id></nlm-citation></ref><ref id="ref53"><label>53</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names> </name><name name-style="western"><surname>Glasziou</surname><given-names>PP</given-names> </name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names> </name><etal/></person-group><article-title>Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide</article-title><source>BMJ</source><year>2014</year><month>03</month><day>7</day><volume>348</volume><fpage>g1687</fpage><pub-id pub-id-type="doi">10.1136/bmj.g1687</pub-id><pub-id pub-id-type="medline">24609605</pub-id></nlm-citation></ref><ref id="ref54"><label>54</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberg</surname><given-names>AL</given-names> </name><name name-style="western"><surname>Mahoney</surname><given-names>DW</given-names> </name></person-group><article-title>Linear mixed effects models</article-title><source>Methods Mol Biol</source><year>2007</year><volume>404</volume><fpage>213</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/978-1-59745-530-5_11</pub-id><pub-id pub-id-type="medline">18450052</pub-id></nlm-citation></ref><ref id="ref55"><label>55</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>RW</given-names> </name></person-group><article-title>A protection motivation theory of fear appeals and attitude change1</article-title><source>J Psychol</source><year>1975</year><month>09</month><volume>91</volume><issue>1</issue><fpage>93</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1080/00223980.1975.9915803</pub-id><pub-id pub-id-type="medline">28136248</pub-id></nlm-citation></ref><ref id="ref56"><label>56</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soellner</surname><given-names>M</given-names> </name><name name-style="western"><surname>Koenigstorfer</surname><given-names>J</given-names> </name></person-group><article-title>Compliance with medical recommendations depending on the use of artificial intelligence as a diagnostic method</article-title><source>BMC Med Inform Decis Mak</source><year>2021</year><month>08</month><day>6</day><volume>21</volume><issue>1</issue><fpage>236</fpage><pub-id pub-id-type="doi">10.1186/s12911-021-01596-6</pub-id><pub-id pub-id-type="medline">34362359</pub-id></nlm-citation></ref><ref id="ref57"><label>57</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reis</surname><given-names>M</given-names> </name><name name-style="western"><surname>Reis</surname><given-names>F</given-names> </name><name name-style="western"><surname>Kunde</surname><given-names>W</given-names> </name></person-group><article-title>Influence of believed AI involvement on the perception of digital medical advice</article-title><source>Nat Med</source><year>2024</year><month>11</month><volume>30</volume><issue>11</issue><fpage>3098</fpage><lpage>3100</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-03180-7</pub-id><pub-id pub-id-type="medline">39054373</pub-id></nlm-citation></ref><ref id="ref58"><label>58</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>A</given-names> </name><name name-style="western"><surname>Ngo</surname><given-names>M</given-names> </name><name name-style="western"><surname>Thomas</surname><given-names>C</given-names> </name></person-group><article-title>Assessment of patient perceptions of artificial intelligence use in dermatology: a cross-sectional survey</article-title><source>Skin Res Technol</source><year>2024</year><month>03</month><volume>30</volume><issue>3</issue><fpage>e13656</fpage><pub-id pub-id-type="doi">10.1111/srt.13656</pub-id><pub-id pub-id-type="medline">38481072</pub-id></nlm-citation></ref><ref id="ref59"><label>59</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>OT</given-names> </name><name name-style="western"><surname>Calanzani</surname><given-names>N</given-names> </name><name name-style="western"><surname>Scott</surname><given-names>SE</given-names> </name><name name-style="western"><surname>Matin</surname><given-names>RN</given-names> </name><name name-style="western"><surname>Emery</surname><given-names>J</given-names> </name><name name-style="western"><surname>Walter</surname><given-names>FM</given-names> </name></person-group><article-title>User and developer views on using AI technologies to facilitate the early detection of skin cancers in primary care settings: Qualitative semistructured interview study</article-title><source>JMIR Cancer</source><year>2025</year><month>01</month><day>28</day><volume>11</volume><fpage>e60653</fpage><pub-id pub-id-type="doi">10.2196/60653</pub-id><pub-id pub-id-type="medline">39874580</pub-id></nlm-citation></ref><ref id="ref60"><label>60</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peabody</surname><given-names>JW</given-names> </name><name name-style="western"><surname>Luck</surname><given-names>J</given-names> </name><name name-style="western"><surname>Glassman</surname><given-names>P</given-names> </name><name name-style="western"><surname>Dresselhaus</surname><given-names>TR</given-names> </name><name name-style="western"><surname>Lee</surname><given-names>M</given-names> </name></person-group><article-title>Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality</article-title><source>JAMA</source><year>2000</year><month>04</month><day>5</day><volume>283</volume><issue>13</issue><fpage>1715</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1001/jama.283.13.1715</pub-id><pub-id pub-id-type="medline">10755498</pub-id></nlm-citation></ref><ref id="ref61"><label>61</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hainmueller</surname><given-names>J</given-names> </name><name name-style="western"><surname>Hangartner</surname><given-names>D</given-names> </name><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names> </name></person-group><article-title>Validating vignette and conjoint survey experiments against real-world behavior</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><month>02</month><day>24</day><volume>112</volume><issue>8</issue><fpage>2395</fpage><lpage>2400</lpage><pub-id pub-id-type="doi">10.1073/pnas.1416587112</pub-id><pub-id pub-id-type="medline">25646415</pub-id></nlm-citation></ref><ref id="ref62"><label>62</label><nlm-citation citation-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Stone-Romero</surname><given-names>EF</given-names> </name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Rogelberg</surname><given-names>SG</given-names> </name></person-group><article-title>The relative validity and usefulness of various empirical research designs</article-title><source>Handbook of Research Methods in Industrial and Organizational Psychology</source><year>2002</year><publisher-name>Blackwell</publisher-name><fpage>77</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1002/9780470756669</pub-id></nlm-citation></ref><ref id="ref63"><label>63</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thom</surname><given-names>DH</given-names> </name><name name-style="western"><surname>Wong</surname><given-names>ST</given-names> </name><name name-style="western"><surname>Guzman</surname><given-names>D</given-names> </name><etal/></person-group><article-title>Physician trust in the patient: development and validation of a new measure</article-title><source>Ann Fam Med</source><year>2011</year><volume>9</volume><issue>2</issue><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1370/afm.1224</pub-id><pub-id pub-id-type="medline">21403142</pub-id></nlm-citation></ref></ref-list><app-group><supplementary-material id="app1"><label>Multimedia Appendix 1</label><p>Instruction before starting the main experiment.</p><media xlink:href="mhealth_v14i1e93991_app1.docx" xlink:title="DOCX File, 27 KB"/></supplementary-material><supplementary-material id="app2"><label>Multimedia Appendix 2</label><p>Motivation condition stimuli.</p><media xlink:href="mhealth_v14i1e93991_app2.docx" xlink:title="DOCX File, 340 KB"/></supplementary-material><supplementary-material id="app3"><label>Multimedia Appendix 3</label><p>Loading pages of the mobile health app.</p><media xlink:href="mhealth_v14i1e93991_app3.docx" xlink:title="DOCX File, 149 KB"/></supplementary-material><supplementary-material id="app4"><label>Multimedia Appendix 4</label><p>Document of changes to preregistration.</p><media xlink:href="mhealth_v14i1e93991_app4.docx" xlink:title="DOCX File, 16 KB"/></supplementary-material><supplementary-material id="app5"><label>Multimedia Appendix 5</label><p>Tests and estimates of fixed effects.</p><media xlink:href="mhealth_v14i1e93991_app5.docx" xlink:title="DOCX File, 20 KB"/></supplementary-material><supplementary-material id="app6"><label>Multimedia Appendix 6</label><p>Coefficients from the cumulative link mixed model examining advice source, risk assessment, and motivational context.</p><media xlink:href="mhealth_v14i1e93991_app6.docx" xlink:title="DOCX File, 15 KB"/></supplementary-material><supplementary-material id="app7"><label>Multimedia Appendix 7</label><p>Coefficients from the cumulative link mixed model examining trust and advice source.</p><media xlink:href="mhealth_v14i1e93991_app7.docx" xlink:title="DOCX File, 15 KB"/></supplementary-material><supplementary-material id="app8"><label>Checklist 1</label><p>CONSORT-EHEALTH checklist.</p><media xlink:href="mhealth_v14i1e93991_app8.pdf" xlink:title="PDF File, 3812 KB"/></supplementary-material></app-group></back></article>